Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177996 · ClinicalTrials.gov registry record · Phase 4
Pharmacotherapy in Depression With Panic Spectrum
A Phase 4 study of Major Depression, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00177996 is a Phase 4 study of Major Depression that has completed, run by University of Pittsburgh. The registered enrollment target is 30 participants, below the 326-participant average among 28 other Major Depression trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00177996, a Phase 4 study of Major Depression, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is being conducted to find out if certain individuals benefit from taking medication for their depression with a low dose of the antidepressant medication Zoloft.
Conditions Studied
Interventions
- DRUG sertraline hydrochloride
Study Locations (1)
Pennsylvania
- Western Psychiatric Insititue and Clinic - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2001-10 |
| Est. Completion | 2007-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00177996
The ClinicalTrials.gov registry entry for NCT00177996 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 326-participant average among 28 other Major Depression trials with a reported enrollment target (91% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depression appearing as the primary indexed condition, and to 1 intervention - of which sertraline hydrochloride is the first listed.
NCT00177996 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00177996 about?
NCT00177996 is a clinical study titled "Pharmacotherapy in Depression With Panic Spectrum". This research study is being conducted to find out if certain individuals benefit from taking medication for their depression with a low dose of the antidepressant medication Zoloft.
What is the current status of trial NCT00177996?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2001-10. Estimated completion is 2007-01.
What conditions does trial NCT00177996 study?
This clinical trial studies the following conditions: Major Depression.
What interventions are being tested in trial NCT00177996?
The interventions under investigation include: sertraline hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00177996?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00177996 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.
COMPLETED · Phase 4
-
Preventing Depression Recurrence in Diabetes
COMPLETED · Phase 4
-
Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram
COMPLETED · Phase 4
-
Prozac Treatment of Major Depression: Discontinuation Study
COMPLETED · Phase 4
-
Thyroid Medication and Antidepressants for Treating Major Depression
COMPLETED · Phase 4
-
The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.